• Please log in or register to access this feature.

Original Article

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors†‡

Results of a multicenter phase 2 trial

  1. Andrew J. Wagner MD, PhD1,§,¶,*,
  2. John M. Goldberg MD2,§,
  3. Steven G. DuBois MD3,
  4. Edwin Choy MD4,
  5. Lee Rosen MD5,
  6. Alberto Pappo MD6,
  7. James Geller MD7,
  8. Ian Judson MD8,
  9. David Hogg MD9,
  10. Neil Senzer MD10,
  11. Ian J. Davis MD, PhD11,
  12. Feng Chai MD12,
  13. Carol Waghorne12,
  14. Brian Schwartz MD12,
  15. George D. Demetri MD1

Article first published online: 17 MAY 2012

DOI: 10.1002/cncr.27582

Issue

Cancer

Cancer

Volume 118, Issue 23, pages 5894–5902, 1 December 2012

Additional Information

How to Cite

Wagner, A. J., Goldberg, J. M., DuBois, S. G., Choy, E., Rosen, L., Pappo, A., Geller, J., Judson, I., Hogg, D., Senzer, N., Davis, I. J., Chai, F., Waghorne, C., Schwartz, B. and Demetri, G. D. (2012), Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors. Cancer, 118: 5894–5902. doi: 10.1002/cncr.27582

Author Information

  1. 1

    Dana-Farber Cancer Institute, Boston, Massachusetts

  2. 2

    University of Miami, Miller School of Medicine, Miami, Florida

  3. 3

    University of California San Francisco, School of Medicine, San Francisco, California

  4. 4

    Massachusetts General Hospital, Boston, Massachusetts

  5. 5

    University of California Los Angeles, Santa Monica, California

  6. 6

    St. Jude Children's Research Hospital, Memphis, Tennessee

  7. 7

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

  8. 8

    The Royal Marsden NHS Foundation Trust, London, United Kingdom

  9. 9

    University of Toronto, Toronto, Canada

  10. 10

    Mary Crowley Cancer Research Centers, Dallas, Texas

  11. 11

    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina

  12. 12

    ArQule, Inc., Woburn, Massachusetts

  1. §

    The first 2 authors contributed equally to this work.

  2. Fax: (617) 632-3408

*Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215

  1. †

    We are extremely grateful to the patients participating in this study and to their family members, as well as to the coinvestigators and study teams at each site. We thank Bret Wing, PhD, ProEd Communications, Inc., for his medical editorial assistance with this manuscript.

  2. ‡

    Trial registered at ClinicalTrials.gov (identifier NCT00557609).

  3. §

    The first 2 authors contributed equally to this work.

  4. Fax: (617) 632-3408

Publication History

  1. Issue published online: 19 NOV 2012
  2. Article first published online: 17 MAY 2012
  3. Manuscript Accepted: 27 FEB 2012
  4. Manuscript Revised: 2 FEB 2012
  5. Manuscript Received: 11 NOV 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (322K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ulka Vaishampayan, Cabozantinib as a Novel Therapy for Renal Cell Carcinoma, Current Oncology Reports, 2013, 15, 2, 76

    CrossRef

  2. 2
    Jeffrey S. Dome, Conrad V. Fernandez, Elizabeth A. Mullen, John A. Kalapurakal, James I. Geller, Vicki Huff, Eric J. Gratias, David B. Dix, Peter F. Ehrlich, Geetika Khanna, Marcio H. Malogolowkin, James R. Anderson, Arlene Naranjo, Elizabeth J. Perlman, Children's Oncology Group's 2013 blueprint for research: Renal tumors, Pediatric Blood & Cancer, 2013, 60, 6
    Direct Link:
  3. 3
    Eric A. Singer, Gopal N. Gupta, Daniel Marchalik, Ramaprasad Srinivasan, Evolving therapeutic targets in renal cell carcinoma, Current Opinion in Oncology, 2013, 1

    CrossRef

  4. 4
    Richard M. Bambury, Jodie E. Battley, Aoife McCarthy, Claire Brady, Seamus O'Reilly, Paul J. Kelly, Frank O'Brien, Paul Sweeney, Stewart Fleming, Nick J. Mayer, Derek G. Power, Translocation Renal Cell Carcinomas: An Evolving Entity and a Member of the Microphthalmia Transcription Factor-Associated Family of Tumors, Clinical Genitourinary Cancer, 2013,

    CrossRef

View Full Article (HTML) Get PDF (322K)